Giant Cell Tumor of the Bone in Young Patients

Giant Cell Tumor of the Bone in Patients Under 15 Years Old: a Single Institution Case-series

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04002817

Enrollment

Registered

2019-07-01

Start date

2019-06-05

Completion date

2020-06-30

Last updated

2021-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Giant Cell Tumor of Bone

Brief summary

single institution cases series review of histological and clinical data of young patient with Giant Cell Tumors

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 15 Years

Healthy volunteers

Inclusion criteria

1. Male and female patients under 15 years old treated at Rizzoli Institute from 01 January 1982 to 31 December 2018. 2. Diagnosis of giant cell tumor of bone, aneurysmatic bone cysts with solid features and giant cell reparative granuloma. 3. Histological slides/formalin-fixed paraffin-embedded tissue tumor blocks from archive available to perform the histology analysis 4. Written informed consent prior to any study-specific analysis and/or data collection

Exclusion criteria

1. Patients with histological diagnosis different from diagnosis of giant cell tumor, aneurysmatic bone cysts with solid features, and giant cell reparative granuloma. 2. Patients with no available material for additional immunohistochemical and molecular analysis

Design outcomes

Primary

Measure	Time frame	Description
selection and review of 50 cases of young patients with Giant Cell Tumor of bone.	at baseline (Day0)	Investigators will review all the medical records, radiological imaging, and histological slides of all cases in order to collect the largest pediatric series.

Secondary

Measure	Time frame	Description
analysis of H3F3A mutation expression on tissue tumor material	at baseline (Day0)	In all cases with enough available material, immunohistochemistry will be performed on tumor tissue material. Histone 3.3 (H3.3) genes, and H3F3A mutation will be analyzed with immunohistochemistry and/or by allele specific-PCR analysis in order to confirm that the lesions are a giant cell tumors of bone occurring in a non-canonic age group (skeletally immature patients).

Countries

Italy

Outcome results